Cargando…

Increase in endogenous glucose production with SGLT2 inhibition is attenuated in individuals who underwent kidney transplantation and bilateral native nephrectomy

AIMS/HYPOTHESIS: The glucosuria induced by sodium–glucose cotransporter 2 (SGLT2) inhibition stimulates endogenous (hepatic) glucose production (EGP), blunting the decline in HbA(1c). We hypothesised that, in response to glucosuria, a renal signal is generated and stimulates EGP. To examine the effe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Daniele, Giuseppe, Solis-Herrera, Carolina, Dardano, Angela, Mari, Andrea, Tura, Andrea, Giusti, Laura, Kurumthodathu, Jancy J., Campi, Beatrice, Saba, Alessandro, Bianchi, Anna Maria, Tregnaghi, Carla, Egidi, Maria Francesca, Abdul-Ghani, Muhammad, DeFronzo, Ralph, Del Prato, Stefano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7527374/ https://www.ncbi.nlm.nih.gov/pubmed/32827269 http://dx.doi.org/10.1007/s00125-020-05254-w

Ejemplares similares

Novel Hypothesis to Explain Why SGLT2 Inhibitors Inhibit Only 30–50% of Filtered Glucose Load in Humans
por: Abdul-Ghani, Muhammad A., et al.
Publicado: (2013)

Why Do SGLT2 Inhibitors Inhibit Only 30–50% of Renal Glucose Reabsorption in Humans?
por: Liu, Jiwen (Jim), et al.
Publicado: (2012)

Type 2 Diabetes Can Be Prevented With Early Pharmacological Intervention
por: DeFronzo, Ralph A., et al.
Publicado: (2011)

Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm
por: Abdul-Ghani, Muhammad, et al.
Publicado: (2017)

Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 Inhibitors
por: Alatrach, Mariam, et al.
Publicado: (2020)

Pathogenesis of Insulin Resistance in Skeletal Muscle
por: Abdul-Ghani, Muhammad A., et al.
Publicado: (2010)

Plasma Glucose Concentration and Prediction of Future Risk of Type 2 Diabetes
por: Abdul-Ghani, Muhammad A., et al.
Publicado: (2009)

Erratum. Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived? Diabetes Care 2017;40:813–820
por: Abdul-Ghani, Muhammad, et al.
Publicado: (2017)

Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?
por: Abdul-Ghani, Muhammad, et al.
Publicado: (2017)

In Vivo Actions of Peroxisome Proliferator–Activated Receptors: Glycemic control, insulin sensitivity, and insulin secretion
por: Eldor, Roy, et al.
Publicado: (2013)

Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2013)

One-Hour Plasma Glucose Concentration and the Metabolic Syndrome Identify Subjects at High Risk for Future Type 2 Diabetes
por: Abdul-Ghani, Muhammad A., et al.
Publicado: (2008)

Establishment of Renal Failure Models by Laparoscopy in Bama Pigs Which Underwent Partial Nephrectomy and Radical Contralateral Nephrectomy
por: Liu, Hai-Feng, et al.
Publicado: (2019)

Type 1 diabetes and COVID-19: The “lockdown effect”
por: Aragona, Michele, et al.
Publicado: (2020)

Distinct β-Cell Defects in Impaired Fasting Glucose and Impaired Glucose Tolerance
por: Kanat, Mustafa, et al.
Publicado: (2012)

Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes
por: Dardano, Angela, et al.
Publicado: (2014)

Insulin as an Early Treatment for Type 2 Diabetes: ORIGIN or end of an old question?
por: Del Prato, Stefano, et al.
Publicado: (2013)

Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009
por: DeFronzo, R. A.
Publicado: (2010)

From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
por: DeFronzo, Ralph A.
Publicado: (2009)

Bromocriptine: A Sympatholytic, D2-Dopamine Agonist for the Treatment of Type 2 Diabetes
por: DeFronzo, Ralph A.
Publicado: (2011)

Impact of COVID-19 lockdown on glucose control of elderly people with type 2 diabetes in Italy
por: Falcetta, Pierpaolo, et al.
Publicado: (2021)

Empagliflozin Treatment Is Associated With Improved β-Cell Function in Type 2 Diabetes Mellitus
por: Al Jobori, Hussein, et al.
Publicado: (2018)

Fasting Versus Postload Plasma Glucose Concentration and the Risk for Future Type 2 Diabetes: Results from the Botnia Study
por: Abdul-Ghani, Muhammad A., et al.
Publicado: (2009)

Long-term effect of acute ischemic injury on the kidney underwent clamped partial nephrectomy
por: Zhou, Zhaohui, et al.
Publicado: (2023)

Increased lipid availability for three days reduces whole body glucose uptake, impairs muscle mitochondrial function and initiates opposing effects on PGC-1α promoter methylation in healthy subjects
por: Eldor, Roy, et al.
Publicado: (2017)

The Impact of Vitamin D Deficiency on Retinopathy and Hearing Loss among Type 2 Diabetic Patients
por: Bener, Abdulbari, et al.
Publicado: (2018)

Skeletal Muscle Insulin Resistance Is the Primary Defect in Type 2 Diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2009)

Visceral fat dominant distribution in male type 2 diabetic patients is closely related to hepatic insulin resistance, irrespective of body type
por: Miyazaki, Yoshinori, et al.
Publicado: (2009)

Is Incretin-Based Therapy Ready for the Care of Hospitalized Patients With Type 2 Diabetes?: The time has come for GLP-1 receptor agonists!
por: Schwartz, Stanley, et al.
Publicado: (2013)

A novel experimental model for human mixed acinar–ductal pancreatic cancer
por: Doiron, Bruno, et al.
Publicado: (2018)

FRI607 SGLT2 Inhibition Improves Muscle Oxidative Capacity And Its Relationship With Cardiac Performance In Patients With T2D And Heart Failure
por: Qin, Yuejuan, et al.
Publicado: (2023)

Metformin: an inexpensive and effective treatment in people with diabetes and COVID-19?
por: Dardano, Angela, et al.
Publicado: (2021)

From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes
por: Mosenzon, Ofri, et al.
Publicado: (2021)

PSUN299 GLP-1 Contribution to Insulin Secretory Response to Protein Ingestion and Insulin Kinetics Following Gastric Bypass and Sleeve Gastrectomy
por: Rayas, Maria, et al.
Publicado: (2022)

Renal Artery Embolization Before Radical Nephrectomy for Complex Renal Tumour: Which are the True Advantages?
por: Cochetti, Giovanni, et al.
Publicado: (2019)

Near-Infrared Spectroscopy: A Free-Living Neuroscience Tool to Better Understand Diabetes and Obesity
por: Rebelos, Eleni, et al.
Publicado: (2023)

A Fluorescent Glucose Transport Assay for Screening SGLT2 Inhibitors in Endogenous SGLT2-Expressing HK-2 Cells
por: Lu, Yan-Ting, et al.
Publicado: (2018)

Minimal Contribution of Fasting Hyperglycemia to the Incidence of Type 2 Diabetes in Subjects With Normal 2-h Plasma Glucose
por: Abdul-Ghani, Muhammad A., et al.
Publicado: (2010)

Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2022)

Altered Insulin Clearance after Gastric Bypass and Sleeve Gastrectomy in the Fasting and Prandial Conditions
por: Salehi, Marzieh, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_62sov1elpig4rf1hor1uqj247o